Sex-specific Prevalence of coronary heart disease among Tehranian adult population across different glycemic status: Tehran Lipid and Glucose Study, 2008-2011

Abstract

Background: Coronary heart disease (CHD) is one of the most common causes of deaths and alarmingly Iranian populations had a high rank of CHD worldwide. The object of the current study is to assess the prevalence of CHD, including clinical CHD and silent myocardial infarction (MI) across different glycemic categories.Methods: This study was conducted on 7,368 Tehranian participants (Men=3312), aged ≥ 30 years from 2008 to 2011. Clinical CHD was defined as hospital records which approved by an outcome committee. Using Minnesota Code ECG classifications, silent MI was defined by appearance of major abnormal Q/QS waves (MC 1.1 or MC 1.2), or minor abnormal Q/QS waves (MC 1.3) plus major abnormal ST-T (MC 4.1, MC 4.2, MC 5.1 or MC 5.2.)Results: Among the total population, the age-standardized prevalence of CHD was 12.82% [confidence interval (CI) 95%:12.11-13.53]. The age-standardized prevalences of total CHD, clinical CHD and silent MI were 13.42% (12.33-14.5), 9.69% (8.81-10.56) and 3.73% (3.04-4.43) for men and were 12.70% (11.73-13.66), 8.56% (7.79-9.33) and 4.14% (3.50-4.78) for women, respectively. Moreover, 17.67% (13.90-21.44) of the male and 18.94% (14.59-23.30) of the female diabetic population had CHD. Specifically, the prevalence of total CHD among known and newly diagnosed diabetic populations and those with combined impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) were 19.53% (15.22-23.84), 16.12% (12.29-19.94) and 16.84% (11.85-21.83), respectively. Compared to other glycemic categories, the prevalence of silent MI was higher among those with combined IFG and IGT (6.80 (2.84-10.76)), although it didn’t reach a significant level.Conclusion: The high prevalence of CHD, especially among those suffering from both IFG and IGT and diabetic populations, necessitates urgent implementation behavioral interventions among Tehranian populations, evidence based on guidelines for clinical management of diabetic patients.